


NOW ENROLLING

FOOD ALLERGY
RESEARCH STUDY

OUTMATCH: Omalizumab as monotherapy and as adjunct therapy to multi-allergen OIT in food allergic children and adults

A phase 3, multicenter, randomized, double-blind, placebo-controlled study in participants who are allergic to peanut and at least two other foods (including milk, egg, wheat, cashew, hazelnut, or walnut).¹



Selected key inclusion criteria¹:

- Aged 1-55 years, with signed informed consent and/or assent
- Allergic to peanut and at least 2 of the following foods based on DBPCFC: milk, egg, wheat, cashew, hazelnut, walnut
- Eligibility for omalizumab dosing, according to the study drug-dosing table

Selected key exclusion criteria¹:

- Dose-limiting symptoms to the placebo portion of the screening DBPCFC
- Sensitivity or suspected/known allergy to omalizumab
- Poorly controlled atopic dermatitis at screening
- Poorly controlled or severe asthma/wheezing at screening
- History of severe anaphylaxis to participant-specific foods used in this study

Primary efficacy endpoint:

To compare the ability to consume foods without dose-limiting symptoms during a DBPCFC, after treatment with either omalizumab or placebo for omalizumab for 16 weeks.¹

Product under investigation has not been approved for use outside the clinical trial setting. This information is presented only for the purpose of providing an overview of the clinical trials and should not be construed as a recommendation for use of any product for unapproved purposes.

For more information on trial inclusion and exclusion criteria visit www.clinicaltrials.gov.

DBPCFC=double-blind placebo-controlled food challenge; OFC=oral food challenge; OIT=oral immunotherapy; OMA=omalizumab.

OUTMATCH is supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health); Genentech, a member of the Roche Group; and Novartis Pharmaceuticals Corporation.



**CONSORTIUM FOR
FOOD ALLERGY RESEARCH**
NIH Sponsored

If you have patients who are interested in participating,
please contact the appropriate study site below

ARKANSAS**Arkansas Children's Hospital Research Institute:
Department of Pediatrics, Allergy & Immunology**

Little Rock, Arkansas 72202
Darlene Robertson | 501-364-3749 |
LDRobertson@uams.edu

CALIFORNIA**Stanford School of Medicine: Sean N. Parker
Center for Allergy & Asthma Research**

Stanford, California 94305
MacKenzie Cox | 650-724-0293 | MKCox@stanford.edu

COLORADO**National Jewish Health: Division of Pediatric
Allergy and Clinical Immunology**

Denver, Colorado 80206
Caroline Bronchick | 303-270-2207 |
BronchickC@njhealth.org
Susan Leung | 303-398-1549 | LeungS@njhealth.org

GEORGIA**Emory University School of Medicine:
Children's Healthcare of Atlanta Pediatrics**

Atlanta, Georgia 30307
Mary Vess | 404-785-4476 | Mary.Vess@choa.org
Ashley Dulson | 404-785-5437 | Ashley.Dulson@choa.org

MARYLAND**Johns Hopkins Children's Center:
Department of Allergy & Immunology**

Baltimore, Maryland 21287
Maureen Jones | 410-502-1711 | MJone241@jhmi.edu

MASSACHUSETTS**Massachusetts General Hospital: Department
of Medicine: Allergy & Clinical Immunology Unit**

Boston, Massachusetts 02114
Michael Marget | 617-643-5833 | MMarget@mgh.harvard.edu

NEW YORK**Icahn School of Medicine at Mount Sinai:
Department of Pediatrics Allergy & Immunology**

New York, New York 10029
Jaime Ross, RN, MSN | 212-241-6577 |
Jaime.Ross@mssm.edu

NORTH CAROLINA**North Carolina Children's Hospital: Department
of Pediatrics, Division of Allergy, Immunology
and Rheumatology**


Chapel Hill, North Carolina 27599
Sarah Bennick, MSN, APRN, CPNP | 919-962-4409 |
SBennick@email.unc.edu
Lauren Herlihy, RN, MSN, CPNP | 919-962-4406 |
LekocH@email.unc.edu

PENNSYLVANIA**Children's Hospital of Philadelphia: Division
of Allergy and Immunology**

Philadelphia, Pennsylvania 19104
Noreen Dugan | 267-425-0100 | DuganN@email.chop.edu

TEXAS**University of Texas Southwestern Medical Center:
Division of Allergy and Immunology**

Dallas, Texas 75390
Amy Arneson | 214-456-1438 | Amy.Arneson@childrens.com
Kaylee Lirely | 214-456-3971 | Kaylee.Lirely@childrens.com



Consistent with clinicaltrials.gov as of February 2020.

Product under investigation has not been approved for use outside the clinical trial setting. This information is presented only for the purpose of providing an overview of the clinical trials and should not be construed as a recommendation for use of any product for unapproved purposes.

For more information on trial inclusion and exclusion criteria visit www.clinicaltrials.gov.

Reference: 1. Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (OUtMATCH). [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/NCT03881696). <https://clinicaltrials.gov/ct2/show/NCT03881696>. Published March 19, 2019. Updated January 18, 2020. Accessed January 24, 2020.

**LEAD STUDY PRIMARY
INVESTIGATOR:****Dr. Robert Wood, MD**

Contact #: 410-502-1711

JHM IRB #: 00203850